Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Alendronate treatment for osteoporosis: a review of the clinical evidence.

Literature DB >> 9116385

Alendronate treatment for osteoporosis: a review of the clinical evidence.

Abstract

Bisphosphonates have recently gained an increasing role in the management of osteoporosis. The aminobisphosphonate, alendronate has recently been introduced as a new agent for the treatment of postmenopausal osteoporosis. This paper reviews the clinical evidence for the use of this agent and seeks to assess its place in osteoporosis management.

Entities: Chemical Disease

Mesh：

Substances：
Alendronate

Year: 1996 PMID： 9116385 DOI： 10.1007/bf01629572

Source DB: PubMed Journal: Osteoporos Int ISSN： 0937-941X Impact factor: 4.507

34 in total

1. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.

Authors: D P O'Doherty; D R Bickerstaff; E V McCloskey; N A Hamdy; M N Beneton; S Harris; M Mian; J A Kanis
Journal: J Bone Miner Res Date: 1990-05 Impact factor: 6.741

2. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate.

Authors: C J Gibbs; J E Aaron; M Peacock
Journal: Br Med J (Clin Res Ed) Date: 1986-05-10

3. Short-term effects on bone and mineral metabolism of 4-amino-1-hydroxybutylidene-1,1-diphosphonate (ABDP) in Paget's disease of bone.

Authors: M Pedrazzoni; E Palummeri; G Ciotti; L Davoli; G Pioli; G Girasole; M Passeri
Journal: Bone Miner Date: 1989-11

4. Design of the Fracture Intervention Trial.

Authors: D M Black; T F Reiss; M C Nevitt; J Cauley; D Karpf; S R Cummings
Journal: Osteoporos Int Date: 1993 Impact factor: 4.507

5. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors: U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal: N Engl J Med Date: 1995-11-30 Impact factor: 91.245

6. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

Authors: J P Devogelaer; H Broll; R Correa-Rotter; D C Cumming; C N De Deuxchaisnes; P Geusens; D Hosking; P Jaeger; J M Kaufman; M Leite; J Leon; U Liberman; C J Menkes; P J Meunier; I Reid; J Rodriguez; A Romanowicz; E Seeman; A Vermeulen; L J Hirsch; A Lombardi; K Plezia; A C Santora; A J Yates; W Yuan
Journal: Bone Date: 1996-02 Impact factor: 4.398

7. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.

Authors: G Attardo-Parrinello; G Merlini; F Pavesi; F Crema; M L Fiorentini; E Ascari
Journal: Arch Intern Med Date: 1987-09

8. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.

Authors: P Garnero; W J Shih; E Gineyts; D B Karpf; P D Delmas
Journal: J Clin Endocrinol Metab Date: 1994-12 Impact factor: 5.958

Alendronate treatment for osteoporosis: a review of the clinical evidence.

1. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.

2. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate.

3. Short-term effects on bone and mineral metabolism of 4-amino-1-hydroxybutylidene-1,1-diphosphonate (ABDP) in Paget's disease of bone.

4. Design of the Fracture Intervention Trial.

5. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

6. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

7. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.

8. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.

9. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy.

10. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.

1. [Chronic mouth ulcer due to inadequate ingestion of alendronate].

2. Influence of alendronate and endplate degeneration to single level posterior lumbar spinal interbody fusion.